Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental blood thinner tested in heart attack emergency

NCT ID NCT00546260

Disease control Sponsor: Alexion Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested an intravenous antiplatelet drug called PRT060128 in 70 people having a severe heart attack (STEMI). The goal was to see if giving the drug before emergency artery-opening treatment improved blood flow and was safe. The trial was terminated early, so the full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
PRT060128 (antiplatelet drug)
What this could lead to
If successful, this could point toward a faster-acting antiplatelet option for heart attack patients undergoing emergency artery-opening procedures.
What could go wrong
This was a small, early-phase trial that was terminated, so results are limited. The drug may increase bleeding risk without clear benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

70 people

The number who actually took part.

Start date

Nov 2007

Finished

Jul 2008

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Persistent ST elevation ≥ 1mm (≥ 0.1mV) in two contiguous limb leads OR ≥ 2 mm (≥ 0.2mV) in two contiguous precordial leads, AND chest pain ≥ 20 minutes with onset within 6 hours of hospital presentation. Exclusion Criteria: * Cardiogenic shock (systolic blood pressure \< 90 mm Hg requiring vasopressor or hemodynamic support) * Uncontrolled hypertension defined as any measured systolic blood pressure (SBP) \> 180 mm Hg or diastolic blood pressure (DBP) ≥ 110 mm Hg after the time -- History or symptoms of a congenital or acquired bleeding disorder or vascular malformation. * Recent gastrointestinal bleeding within the last 30 days. * Known thrombocytopenia (platelet count \< 100,000/mm3). * Any treatment with a fibrinolytic agent within the last 7 days.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myocardial infarction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

myocardial infarction ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myocardial infarction

Contacts and locations

Locations

  • Atlantic Health Services

    Saint John, New Brunswick, E2L4L2, Canada

  • Centre Hospitalier Universitaire de Montreal - Hotel Dieu

    Montreal, Quebec, H2W1T8, Canada

  • Foothills Hospital

    Calgary, Alberta, T2N2T9, Canada

  • Geisinger Medical Center

    Danville, Pennsylvania, 17822, United States

  • General Hospital - Heath Sciences Centre

    St. John's, Newfoundland and Labrador, A1B3V6, Canada

  • Genesys Regional Medical Center

    Grand Blanc, Michigan, 48439, United States

  • Hamilton Health Sciences

    Hamilton, Ontario, L8L2X2, Canada

  • Henry Ford Hospital

    Detroit, Michigan, 48202, United States

  • Hospital du Sacre Coeur

    Montreal, Quebec, H4N1C5, Canada

  • Iowa Heart Center

    Des Moines, Iowa, 50314, United States

  • Lindner Clinical Trial Center

    Cincinnati, Ohio, 45219, United States

  • London Health Sciences

    London, Ontario, N6A5A5, Canada

  • Maine Medical Center

    Portland, Maine, 04102, United States

  • Montreal Heart Institute

    Montreal, Quebec, H1T1C8, Canada

  • Queen Elizabeth II Health Sciences Centre

    Halifax, Nova Scotia, B3H3A7, Canada

  • Regina General Hospital

    Regina, Saskatchewan, S4P0W5, Canada

  • Royal Alexandria Hospital

    Edmonton, Alberta, T5H3V7, Canada

  • Soutlake Regional Health Centre

    Newmarket, Ontario, L3Y2R2, Canada

  • St. Joseph Mercy - Oakland

    Pontiac, Michigan, 48341, United States

  • St. Paul's Hospital

    Vancouver, British Columbia, V6Z1Y6, Canada

  • Sunnybrook Health Sciences Centre

    Toronto, Ontario, M4N3M5, Canada

  • Tallahassee Memorial Medical Center

    Tallahassee, Florida, 32308, United States

  • The Heart Center

    Kingsport, Tennessee, 37660, United States

  • Trillium Health Centre - Mississaugua

    Mississauga, Ontario, L5B2P7, Canada

  • University of Alberta Hospital

    Edmonton, Alberta, T6G2B7, Canada

  • University of Kentucky Hospital, Gill Heart Center

    Lexington, Kentucky, 40536, United States

  • Vancouver General Hospital

    Vancouver, British Columbia, V5Z1M9, Canada

  • Victoria Heart Institute, Royal Jubilee Hospital

    Victoria, British Columbia, V8R4R2, Canada

  • Washington Adventist Hospital

    Takoma Park, Maryland, 20912, United States

  • William Beaumont Hospital

    Royal Oak, Michigan, 48073, United States

  • William Beaumont Hospital - Troy Cardiology

    Troy, Michigan, 48085, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.